Literature DB >> 1553343

Development of extended-release solid dispersions of nonsteroidal antiinflammatory drugs with aqueous polymeric dispersions: optimization of drug release via a curve-fitting technique.

C Ho1, G C Hwang.   

Abstract

Extended-release solid dispersions of nonsteroidal antiinflammatory drugs were prepared by using aqueous polymeric dispersions of Eudragit RS30D and Eudragit RL30D as the inert carriers. The effects of different polymer ratios of Eudragit RS30D and Eudragit RL30D, different particle sizes, and different combination of various formulations of solid dispersions on the in vitro release kinetics of drugs from the dosage forms were investigated. A computer curve-fitting process was developed to choose the optimum formulation of the solid dispersion with the desired drug release profile. This process might offer the advantages of efficiency and simplicity in the formulation development of extended-release solid dispersions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1553343     DOI: 10.1023/a:1018933306162

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

1.  MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES.

Authors:  T HIGUCHI
Journal:  J Pharm Sci       Date:  1963-12       Impact factor: 3.534

Review 2.  Pharmaceutical applications of solid dispersion systems.

Authors:  W L Chiou; S Riegelman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

3.  [Solid dispersion obtained from nifedipine and enteric coating agents. I. Dissolution behavior].

Authors:  A Hasegawa; H Nakagawa; I Sugimoto
Journal:  Yakugaku Zasshi       Date:  1984-05       Impact factor: 0.302

4.  Bioavailability and stability of nifedipine-enteric coating agent solid dispersion.

Authors:  A Hasegawa; H Nakagawa; I Sugimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-01       Impact factor: 1.645

  4 in total
  2 in total

1.  Interpolyelectrolyte complexes of Eudragit® EPO with hypromellose acetate succinate and Eudragit® EPO with hypromellose phthalate as potential carriers for oral controlled drug delivery.

Authors:  Balamurugan Jeganathan; Vijayalakshmi Prakya
Journal:  AAPS PharmSciTech       Date:  2015-01-16       Impact factor: 3.246

2.  Formulation of sustained-release dosage form of verapamil hydrochloride by solid dispersion technique using Eudragit RLPO or Kollidon SR.

Authors:  J Sahoo; P N Murthy; S Biswal
Journal:  AAPS PharmSciTech       Date:  2009-01-15       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.